As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of $535, up from $480. Vertex remains well-positioned with a “dominant” cystic fibrosis franchise that the company “has again found a way to extend” with Alyftrek, the analyst tells investors. More broadly, the firm cites improving diversification with a set of recent or near-term launches with “blockbuster potential,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald
- QQQ ETF News, 4/16/2025
- Vertex Pharmaceuticals price target raised to $462 from $459 at Morgan Stanley
- Vertex Pharmaceuticals announces EC approval of expanded KAFTRIO label
- Early notable gainers among liquid option names on April 4th